A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

NCT05822830 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults who have obesity or overweight with weight-related health issues to see how it affects their body weight over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 751 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-04 · est. completion 2024-11

Where 32 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT05822830 ↗

Description as written by the study sponsor.

The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Semaglutide Drug

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05822830 ↗